Bone Fracture

There is a bidirectional relationship between cognitive decline and accelerated bone loss with increased fracture risk among women, according to new data published in the Journal of Bone and Mineral Research.

Postmenopausal women have an increased risk for a subsequent fracture after both traumatic and nontraumatic initial fractures, according to a study published in JAMA Internal Medicine.

Postmenopausal women who sustain any type of initial fracture are at a higher risk for a subsequent fracture, according to a study published in EClinicalMedicine.

A report from the National Osteoporosis Foundation details fracture rates for all 50 U.S. states and highlights ethnic and racial disparities among Medicare beneficiaries for hospitalization, mortality and health costs.

The use of denosumab to treat osteoporosis has increased rapidly since its FDA approval in 2010, and it is now the second most used medication after alendronate, according to data presented at the ENDO annual meeting.

The experience with fluoride made clear that increased BMD does not result in reduced fractures when the mineralization of bone is compromised. Therefore, good data on bone histology is a prerequisite for accepting BMD as a surrogate for fracture. Strontium increases BMD substantially, but this is significantly contributed to by the heavier strontium atoms replacing calcium in bone mineral. Thus, the increase in BMD does not reflect an increase in bone tissue volume, again dissociating BMD from bone strength.

Osteoporotic fractures represent a costly human and socioeconomic burden. Even with currently available drugs, treatments that more effectively increase bone mineral density, reduce fractures and reverse the disease are needed.

A model factoring in age, femoral neck width and lateral cortical width at lesser trochanter may be able to differentiate atypical vs. typical femur fractures in women, according to study data.

Osteoporosis, long considered a disease of older age, is estimated to affect about 25% of women aged at least 65 years, according to the CDC.

The FDA cleared an investigational new drug application for NVD-003, a stem cell therapy for treatment of children with congenital pseudarthrosis of the tibia, according to the agent’s manufacturer.